Vinge has advised Infranity, a private equity firm specializing in infrastructure investments, in connection with its acquisition of a majority stake in Nordic Re-Finance AB, a Scandinavian locomotives lessor. The acquisition brings ambitious development plans for Nordic Re-Finance AB, including expansion into new geographical areas.
Vinge has represented Inflexion in connection with the acquisition of the Mecenat group from IK. The acquisition of Mecenat is the first investment made through Inflexion's new Enterprise Fund VI, and Inflexion's first acquisition in Sweden.
Vinge has advised Stenhus Fastigheter i Norden AB (publ) (“Stenhus Fastigheter” or the “Company”) in connection with the Company's uplisting to Nasdaq Stockholm. The first day of trading on Nasdaq Stockholm was 18 December 2024.
Vinge has advised Apotea AB (publ) (“Apotea”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on November 26, 2024 and the first day of trading is December 6, 2024.
The shareholders of Spring Media have entered into an agreement to sell the shares in Spring Media to Two Circles. Spring Media is an international sports agency operating in, among other things, production, packaging, digital strategies, and rights negotiations in the field of sports rights.
Avima AB is a Swedish specialist in project and information management, with expertise in complex projects within construction, real estate and infrastructure.
Vinge advises Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”) in connection with an offering of new ordinary shares and listing on Nasdaq Stockholm. The first day of trading is 20 June 2024.
Vinge has advised Ikano Bank AB (publ) in connection with the acquisition of a consumer credit unsecured loan portfolio from Nordnet Bank AB. The final purchase price will be based on the outstanding loan volume in the portfolio as of closing date. As of March 2024, the outstanding loan volume in the portfolio amounted to approximately SEK 3.8 billion. The acquisition is subject to customary regulatory approvals.
Vinge has advised Helix Kapital in the establishment of Helix Kapital’s third fund, Helix Kapital Fund III. The fund closed successfully with commitments of approximately SEK 1.5 billion from an international investor base consisting of a number of leading financial institutions. The investor interest in the fund raising was very strong, and the fund was significantly oversubscribed.
Vinge has advised Adelis Equity Partners on the establishment of a continuation fund to Adelis Equity Partners Fund II. The continuation fund is a so-called dual-asset vehicle which will invest in Presto and HVD Group (Hantverksdata) – both current portfolio companies of Adelis Equity Partners Fund II. The continuation fund, in which HarbourVest Partners will be the largest investor, will have EUR 430m in commitments and will invest alongside Adelis Equity Partners Fund III and the Adelis team.
Vinge advises EQT Healthcare Growth, a new dedicated healthcare buy-out strategy introduced by EQT, in connection with its first investment – the acquisition of the biotech company, Mabtech, from IK Small Cap II Fund and several minority sellers.
Vinge has advised Thermo Fisher Scientific Inc., (”Thermo Fisher”), the world leader in serving science, with annual revenue over $40 billion, in connection with its acquisition of Olink Holding AB (publ) (“Olink”).